Brief: Pharnext Announces Publication Of Preclinical Results For Its PLEODRUG (TM) PXT 3003 In PLOS ONE

Pharnext SCA

17/01/2019 07:11

Jan 17 (Reuters) - PHARNEXT SA  PHARN.PA :
    * NEW DATA PUBLISHED IN PLOS ONE DEMONSTRATES EARLY
THERAPEUTIC
EFFECTS OF PHARNEXT'S PLEODRUG(TM) PXT3003 IN A TRANSGENIC RAT
MODEL OF CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
    * LOOKS FORWARD TO INITIATING A PHASE 3 TRIAL OF PXT3003 IN
PEDIATRIC PATIENTS BY END OF 2019
    * INTENDS TO LAUCH A PEDIATRIC PHASE 3 CLINICAL TRIAL IN
CHILDREN
TO INVESTIGATE SAFETY AND EFFICACY OF PXT3003
    * NEW PRECLINICAL RESULTS FOR ITS LEAD PLEODRUG(TM) PXT3003
IN
PLOS ONE SHOWING THAT EARLY TREATMENT WITH PXT3003 IN TRANSGENIC
RAT MODEL DELAYS ONSET OF CMT1A
    * INVESTIGATION PLAN WAS AGREED WITH EUROPEAN MEDICINES
AGENCY

Source text for Eikon:  ID:nEQVY2lya 
Further company coverage:  PHARN.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))